Effect of L-alpha-amino-gamma-guanidinobutyric acid on melphalan therapy of the L1210 murine leukemia.

Abstract

About half the mice administered a lethal inoculum of L1210 leukemia become 60-day survivors when treated with an appropriate dose of melphalan. Leucine completely abolishes this long-term survival by interfering with melphalan uptake into the tumor cells. L-alpha-Amino-gamma-guanidinobutyric acid, the lower homolog of arginine, promotes melphalan uptake in vitro only in the presence of leucine. When administered to mice with melphalan and a dose of leucine which negates the 50% cure rate of melphalan, it reduces the therapeutic interference of leucine. However, L-alpha-Amino-gamma-guanidinobutyric acid alone does not improve melphalan therapy, suggesting that endogenous leucine can play only a minor role in interference with therapy of the L1210 leukemia.

• Authors: D T Vistica, A Rabon, M Rabinovitz
• Journal: Cancer letters (Cancer Lett) Vol. 6 Issue 6 Pg. 345-50 (May 1979) ISSN: 0304-3835 [Print] Ireland
• PMID: 455272 (Publication Type: Journal Article)

Chemical References

• Aminobutyrates
• Guanidines
• Leucine
• Melphalan

Topics

• Aminobutyrates (pharmacology)
• Animals
• Biological Transport, Active (drug effects)
• Drug Interactions
• Drug Therapy, Combination
• Guanidines (pharmacology)
• Leucine (administration & dosage)
• Leukemia L1210 (drug therapy, metabolism)
• Male
• Melphalan (administration & dosage, metabolism)
• Mice
• Mice, Inbred Strains